ATE305507T1 - Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide - Google Patents

Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide

Info

Publication number: ATE305507T1
Authority: AT; Austria
Prior art keywords: hematopoiesis; cpg oligonucleotides; regulating; regulating hematopoiesis; relates
Prior art date: 1998-05-14

Application number

AT99928176T

Other languages

English (en)

Inventor

Hermann Wagner

Grayson Lipford

Original Assignee

Coley Pharm Gmbh

Coley Pharm Group Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-14

Filing date

1999-05-14

Publication date

2005-10-15

1999-05-14 Application filed by Coley Pharm Gmbh, Coley Pharm Group Inc filed Critical Coley Pharm Gmbh

2005-10-15 Application granted granted Critical

2005-10-15 Publication of ATE305507T1 publication Critical patent/ATE305507T1/de

Links

230000011132 hemopoiesis Effects 0.000 title abstract 4
230000001105 regulatory effect Effects 0.000 title abstract 4
108091034117 Oligonucleotide Proteins 0.000 title abstract 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 3
208000007502 anemia Diseases 0.000 abstract 1
210000000987 immune system Anatomy 0.000 abstract 1
230000035921 thrombopoiesis Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Microbiology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

AT99928176T 1998-05-14 1999-05-14 Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide ATE305507T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US8551698P	1998-05-14	1998-05-14
US24165399A	1999-02-02	1999-02-02
PCT/IB1999/001285 WO1999058118A2 (en)	1998-05-14	1999-05-14	METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES

Publications (1)

Publication Number	Publication Date
ATE305507T1 true ATE305507T1 (de)	2005-10-15

Family

ID=26772811

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99928176T ATE305507T1 (de)	1998-05-14	1999-05-14	Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide

Country Status (10)

Country	Link
US (5)	US20040030118A1 (de)
EP (2)	EP1674574A1 (de)
JP (1)	JP2002514397A (de)
AT (1)	ATE305507T1 (de)
AU (1)	AU760795B2 (de)
CA (1)	CA2328406A1 (de)
DE (1)	DE69927495T2 (de)
IL (3)	IL139646A0 (de)
NZ (1)	NZ508650A (de)
WO (1)	WO1999058118A2 (de)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en)	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
CA2244946C (en) *	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
EP0855184A1 (de)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998052581A1 (en)	1997-05-20	1998-11-26	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
JP2002510644A (ja) *	1998-04-03	2002-04-09	ユニバーシティオブアイオワリサーチファウンデーション	免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
CA2328406A1 (en) *	1998-05-14	1999-11-18	Hermann Wagner	Methods for regulating hematopoiesis using cpg-oligonucleotides
IL139813A0 (en) *	1998-05-22	2002-02-10	Loeb Health Res Inst At The Ot	Methods and products for inducing mucosal immunity
US20030022854A1 (en)	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
CA2340174C (en)	1998-08-10	2011-01-04	Antigenics Llc	Compositions of cpg and saponin adjuvants and methods thereof
ATE464907T1 (de) *	1999-02-17	2010-05-15	Csl Ltd	Immunogene komplexe und methoden in bezug auf diese
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
EP1176966B1 (de) *	1999-04-12	2013-04-03	THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES	Oligodeoxynukleotide und deren verwendung zur induktion einer immunreaktion
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
DE60041335D1 (de)	1999-08-19	2009-02-26	Dynavax Tech Corp	Methode zur modulierung eines immunantwortes mit immunstimulierenden sequencen und zusammensetzungen dafür
TR200200797T2 (tr) *	1999-09-25	2002-10-21	University Of Iowa Research Foundation	İmmünostimülatör nükleik asitler
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
DE60131430T2 (de) *	2000-01-14	2008-10-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
WO2001095935A1 (en) *	2000-01-20	2001-12-20	Ottawa Health Research Institute	Immunostimulatory nucleic acids for inducing a th2 immune response
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US7157437B2 (en) *	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en) *	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US20020098199A1 (en) *	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20020107212A1 (en) *	2000-03-10	2002-08-08	Nest Gary Van	Methods of reducing papillomavirus infection using immunomodulatory polynucleotide sequences
US20020028784A1 (en) *	2000-03-10	2002-03-07	Nest Gary Van	Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US6653467B1 (en) *	2000-04-26	2003-11-25	Jcr Pharmaceutical Co., Ltd.	Medicament for treatment of Duchenne muscular dystrophy
WO2001097843A2 (en)	2000-06-22	2001-12-27	University Of Iowa Research Foundation	Methods for enhancing antibody-induced cell lysis and treating cancer
WO2002002172A1 (en) *	2000-06-30	2002-01-10	Univ Jefferson	Dna palindrome - oligoguanylic acid compositions and uses thereof
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
CA2419894A1 (en)	2000-09-15	2002-03-21	Coley Pharmaceutical Gmbh	Process for high throughput screening of cpg-based immuno-agonist/antagonist
AU2001297693A1 (en) *	2000-12-08	2002-09-12	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
US20030055014A1 (en) *	2000-12-14	2003-03-20	Bratzler Robert L.	Inhibition of angiogenesis by nucleic acids
US7087586B2 (en) *	2001-04-24	2006-08-08	Bioniche Life Sciences, Inc.	Oligonucleotide compositions and their use to induce differentiation of cells
US8114418B2 (en)	2001-06-21	2012-02-14	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—IV
US9777312B2 (en)	2001-06-30	2017-10-03	Enzo Life Sciences, Inc.	Dual polarity analysis of nucleic acids
AU2002361468A1 (en)	2001-08-14	2003-03-18	The Government Of The United States Of America As Represented By The Secretary Of Health And Human S	Method for rapid generation of mature dendritic cells
CN1604795B (zh)	2001-08-17	2010-05-26	科勒制药股份公司	具有提高的活性的组合基序免疫刺激寡肽
DE60234375D1 (de)	2001-09-14	2009-12-24	Cytos Biotechnology Ag	VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2002347404A1 (en) *	2001-09-14	2003-04-01	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
US20030139364A1 (en) *	2001-10-12	2003-07-24	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
AU2003230806B2 (en)	2002-04-04	2009-05-07	Zoetis Belgium S.A.	Immunostimulatory G,U-containing oligoribonucleotides
MXPA04010415A (es)	2002-04-22	2005-02-17	Bioniche Life Sciences Inc	Composiciones oligonucleotdias y su uso para la modulacion de respuestas inmunes.
PL375306A1 (en) *	2002-06-20	2005-11-28	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
JP2005532067A (ja) *	2002-07-03	2005-10-27	コーリーファーマシューティカルグループ，インコーポレイテッド	刺激性免疫応答用の核酸組成物
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7576066B2 (en)	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20050209183A1 (en) *	2002-07-25	2005-09-22	Phenion Gmbh & Co. Kg	Cosmetic or pharmaceutical preparations comprising nucleic acids based on non-methylated CPG motifs
AR040996A1 (es)	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
CN1753687A (zh) *	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
WO2004053104A2 (en) *	2002-12-11	2004-06-24	Coley Pharmaceutical Group, Inc.	5’ cpg nucleic acids and methods of use
JP5022028B2 (ja) *	2003-03-26	2012-09-12	サイトス・バイオテクノロジー・アクチェンゲゼルシャフト	メラン−ａペプチドアナログ−ウイルス様粒子コンジュゲート
US7790189B2 (en) *	2003-05-15	2010-09-07	Mitsui Sugar Co., Ltd.	Immunostimulating agents
EA200600069A1 (ru) *	2003-06-20	2006-08-25	Коли Фармасьютикал Гмбх	Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
CN100404070C (zh) *	2003-07-10	2008-07-23	赛托斯生物技术公司	包装的病毒样颗粒
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
MXPA06000619A (es) *	2003-07-15	2006-04-11	Hybridon Inc	Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
SG122973A1 (en) *	2003-10-30	2006-06-29	Coley Pharm Gmbh	C-class oligonucleotide analogs with enhanced immunostimulatory potency
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
US20050256073A1 (en) *	2004-02-19	2005-11-17	Coley Pharmaceutical Group, Inc.	Immunostimulatory viral RNA oligonucleotides
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
CA2567789A1 (en) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
KR100958505B1 (ko) *	2004-07-18	2010-05-17	씨에스엘 리미티드	면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기위한 올리고뉴클레오티드 제제
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
CN101160401A (zh) *	2005-02-24	2008-04-09	科勒制药集团公司	免疫刺激寡核苷酸
WO2006110607A2 (en) *	2005-04-08	2006-10-19	Coley Pharmaceutical Group, Inc.	Methods for treating infectious disease exacerbated asthma
US20060241076A1 (en) *	2005-04-26	2006-10-26	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhanced immunostimulatory activity
PL2380584T3 (pl)	2005-07-01	2014-03-31	Index Pharmaceuticals Ab	Sposób do immunostymulacji
ES2330884T3 (es)	2005-07-01	2009-12-16	Index Pharmaceuticals Ab	Modulacion de la respuesta a los esteroides.
US20090117132A1 (en) *	2005-07-07	2009-05-07	Pfizer, Inc.	Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
WO2007031877A2 (en) *	2005-09-16	2007-03-22	Coley Pharmaceutical Gmbh	Modulation of immunostimulatory properties of short interfering ribonucleic acid (sirna) by nucleotide modification
CN101310019A (zh) *	2005-09-16	2008-11-19	科利制药公司	具有磷酸二酯主链的免疫刺激性单链核糖核酸
EP1940472A1 (de)	2005-10-28	2008-07-09	Index Pharmaceuticals AB	Zusammensetzung und verfahren zur prävention, behandlung und/oder linderung einer entzündlichen erkrankung
US7662949B2 (en) *	2005-11-25	2010-02-16	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
US20070184068A1 (en)	2005-12-14	2007-08-09	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
DK1991678T4 (da) *	2006-02-15	2020-10-19	Rechtsanwalt Thomas Beck	Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer
CN101466720B (zh)	2006-06-12	2013-01-02	赛托斯生物技术公司	向rna噬菌体的病毒样颗粒内包装寡核苷酸的方法
KR101251707B1 (ko)	2006-09-27	2013-04-11	콜리 파마슈티칼 게엠베하	면역 자극 활성이 증강된 소수성 Ｔ 유사체를 함유하는 ＣｐＧ 올리고뉴클레오티드 유사체
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
CN102076358B (zh)	2008-06-27	2016-08-17	硕腾有限责任公司	新颖的佐剂组合物
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
US9394333B2 (en)	2008-12-02	2016-07-19	Wave Life Sciences Japan	Method for the synthesis of phosphorus atom modified nucleic acids
ES2534947T3 (es)	2009-03-25	2015-04-30	The Board Of Regents Of The University Of Texas System	Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
MX342945B (es)	2009-07-06	2016-10-18	Ontorii Inc *	Profármacos de ácido nucleico novedosos y métodos de uso de los mismos.
DK2620428T3 (da)	2010-09-24	2019-07-01	Wave Life Sciences Ltd	Asymmetrisk hjælpegruppe
KR101502200B1 (ko) *	2011-03-03	2015-03-13	충북대학교 산학협력단	쿼르세틴 ３―Ｏ―β―（２＂―갈로일）―람노피란노사이드를 유효성분으로 포함하는 적혈구생성 촉진용 조성물
US9605019B2 (en)	2011-07-19	2017-03-28	Wave Life Sciences Ltd.	Methods for the synthesis of functionalized nucleic acids
KR20240148947A (ko)	2012-07-13	2024-10-11	웨이브 라이프 사이언시스 리미티드	키랄 제어
SG11201500243WA (en)	2012-07-13	2015-04-29	Shin Nippon Biomedical Lab Ltd	Chiral nucleic acid adjuvant
SG11201500239VA (en)	2012-07-13	2015-03-30	Wave Life Sciences Japan	Asymmetric auxiliary group
RU2730011C2 (ru)	2013-09-19	2020-08-14	Зоэтис Сервисиз Ллс	Адъюванты на масляной основе
EP3095460A4 (de)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chirales nukleinsäureadjuvans mit antiallergischer wirkung und antiallergikum
WO2015108047A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
ES2917473T3 (es)	2014-01-16	2022-07-08	Wave Life Sciences Ltd	Diseño quiral
WO2016044839A2 (en)	2014-09-19	2016-03-24	The Board Of Regents Of The University Of Texas System	Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
FI3244920T3 (fi)	2015-01-16	2023-08-04	Zoetis Services Llc	Suu- ja sorkkatautirokote
CA3143533A1 (en) *	2019-08-01	2021-02-04	Madhavan Nallani	A method of eliciting an immune response by administering a population of polymersomes having an associated antigen together with a population of polymersomes having an associated adjuvant as well as compositions comprising the two populations of polymersome
CN117462701A (zh) *	2023-10-31	2024-01-30	暨南大学	一种靶向肝脏的变形红细胞制剂及其制备方法与应用

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2004A (en) *		1841-03-12		Improvement in the manner of constructing and propelling steam-vessels
US3906092A (en) *	1971-11-26	1975-09-16	Merck & Co Inc	Stimulation of antibody response
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5506212A (en) *	1990-01-11	1996-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides with substantially chirally pure phosphorothioate linkages
US5212295A (en) *	1990-01-11	1993-05-18	Isis Pharmaceuticals	Monomers for preparation of oligonucleotides having chiral phosphorus linkages
US5248670A (en) *	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
US5512668A (en) *	1991-03-06	1996-04-30	Polish Academy Of Sciences	Solid phase oligonucleotide synthesis using phospholane intermediates
US5498410A (en) *	1991-04-22	1996-03-12	Gleich; Gerald J.	Method for the treatment of eosinophil-associated conditions with anionic polymers
US5359052A (en) *	1991-08-05	1994-10-25	Polish Academy Of Sciences	Chalcophospholanes useful in the synthesis of oligonucleoside phosphorothioates, phosphorodithioates and related selenates
US5599797A (en) *	1991-10-15	1997-02-04	Isis Pharmaceuticals, Inc.	Oligonucleotides having phosphorothioate linkages of high chiral purity
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
US5849719A (en) *	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
NZ276968A (en) *	1993-11-16	1998-04-27	Genta Inc	Synthetic oligomers enriched for phosphonate internucleosidyl linkages of preselected chirality and their preparation
WO1995026204A1 (en) *	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030050263A1 (en) *	1994-07-15	2003-03-13	The University Of Iowa Research Foundation	Methods and products for treating HIV infection
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
DE69535905D1 (de) *	1994-07-15	2009-02-26	Coley Pharm Group Inc	Immunomodulatorische Oligonukleotide
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
DE69617856T2 (de) *	1995-04-13	2002-06-27	Milkhaus Laboratory, Inc.	Methoden zur behandlung von atemwegserkrankungen
US5750674A (en) *	1995-05-23	1998-05-12	Hybridon, Inc.	Methods and compounds for the stereoselective enrichment of oligonucleotide diastereomers and oligonucleotides thereby produced
US7034007B1 (en) *	1995-06-07	2006-04-25	East Carolina University	Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
US6025339A (en) *	1995-06-07	2000-02-15	East Carolina University	Composition, kit and method for treatment of disorders associated with bronchoconstriction and lung inflammation
US6040296A (en) *	1995-06-07	2000-03-21	East Carolina University	Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
US5780448A (en) *	1995-11-07	1998-07-14	Ottawa Civic Hospital Loeb Research	DNA-based vaccination of fish
CA2244946C (en) *	1996-01-30	2010-04-13	The Regents Of The University Of California	Gene expression vectors which generate an antigen specific immune response and methods of using the same
US20030078223A1 (en) *	1996-01-30	2003-04-24	Eyal Raz	Compositions and methods for modulating an immune response
WO1997040163A1 (en) *	1996-04-19	1997-10-30	Metin Colpan	Nucleic acid vaccination for parvoviral infections
US5856465A (en) *	1996-05-24	1999-01-05	Polska Akademia Nauk Centrum Badan Molekularnych I Makromolekularnych	Compositions and methods for the synthesis of chirally pure organophosphorus nucleoside derivatives
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
EP0930893B1 (de) *	1996-10-11	2005-04-13	The Regents of The University of California	Immunostimulierende oligonucleotidekonjugate
EP0855184A1 (de) *	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmazeutisches Präparat das ein Polynukleotid und ein Antigen enthält, insbesondere zur Impfung
AU738513B2 (en) *	1997-02-28	2001-09-20	University Of Iowa Research Foundation, The	Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) *	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
WO1998052581A1 (en) *	1997-05-20	1998-11-26	Ottawa Civic Hospital Loeb Research Institute	Vectors and methods for immunization or therapeutic protocols
WO1999001154A1 (en) *	1997-07-03	1999-01-14	University Of Iowa Research Foundation	Method for inhibiting immunostimulatory dna associated responses
EP1009413B1 (de) *	1997-09-05	2007-02-14	The Regents Of The University Of California	Verwendung von immunerregenden oligonukleotiden zur vorbeugung oder behandlung von asthma
US6749856B1 (en) *	1997-09-11	2004-06-15	The United States Of America, As Represented By The Department Of Health And Human Services	Mucosal cytotoxic T lymphocyte responses
US20050031638A1 (en) *	1997-12-24	2005-02-10	Smithkline Beecham Biologicals S.A.	Vaccine
JPH11209289A (ja) *	1998-01-22	1999-08-03	Taisho Pharmaceut Co Ltd	粘膜免疫誘起剤
JP2002510644A (ja) *	1998-04-03	2002-04-09	ユニバーシティオブアイオワリサーチファウンデーション	免疫治療用オリゴヌクレオチドおよびサイトカインを用いる免疫系刺激のための方法および産物
EP1077708A1 (de) *	1998-05-06	2001-02-28	University Of Iowa Research Foundation	Methoden zur preventiven und therapeutischen behandlung von parasitären infektionen und damit verbundener krankheiten mittels cpg oligonukleotiden
CA2328406A1 (en) *	1998-05-14	1999-11-18	Hermann Wagner	Methods for regulating hematopoiesis using cpg-oligonucleotides
US6562798B1 (en) *	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en) *	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
ES2259478T3 (es) *	1998-09-18	2006-10-01	Dynavax Technologies Corporation	Metodos para tratar trastornos asociados con la ige y composiciones para este uso.
US6558670B1 (en) *	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
US6514948B1 (en) *	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
US20050249794A1 (en) *	1999-08-27	2005-11-10	Semple Sean C	Compositions for stimulating cytokine secretion and inducing an immune response
TR200200797T2 (tr) *	1999-09-25	2002-10-21	University Of Iowa Research Foundation	İmmünostimülatör nükleik asitler
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
US7223398B1 (en) *	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
US7585847B2 (en) *	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
WO2001097843A2 (en) *	2000-06-22	2001-12-27	University Of Iowa Research Foundation	Methods for enhancing antibody-induced cell lysis and treating cancer
US20020165178A1 (en) *	2000-06-28	2002-11-07	Christian Schetter	Immunostimulatory nucleic acids for the treatment of anemia, thrombocytopenia, and neutropenia
US20020198165A1 (en) *	2000-08-01	2002-12-26	Bratzler Robert L.	Nucleic acids for the prevention and treatment of gastric ulcers
US20020091097A1 (en) *	2000-09-07	2002-07-11	Bratzler Robert L.	Nucleic acids for the prevention and treatment of sexually transmitted diseases
CA2419894A1 (en) *	2000-09-15	2002-03-21	Coley Pharmaceutical Gmbh	Process for high throughput screening of cpg-based immuno-agonist/antagonist
AU2001297693A1 (en) *	2000-12-08	2002-09-12	Coley Pharmaceutical Gmbh	Cpg-like nucleic acids and methods of use thereof
US20030055014A1 (en) *	2000-12-14	2003-03-20	Bratzler Robert L.	Inhibition of angiogenesis by nucleic acids
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
WO2003012061A2 (en) *	2001-08-01	2003-02-13	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
WO2003031573A2 (en) *	2001-10-05	2003-04-17	Coley Pharmaceutical Gmbh	Toll-like receptor 3 signaling agonists and antagonists
US20030139364A1 (en) *	2001-10-12	2003-07-24	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
AU2003230806B2 (en) *	2002-04-04	2009-05-07	Zoetis Belgium S.A.	Immunostimulatory G,U-containing oligoribonucleotides
AU2003243409A1 (en) *	2002-06-05	2003-12-22	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en) *	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AR040996A1 (es) *	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
CN1753687A (zh) *	2002-10-29	2006-03-29	科勒制药集团股份有限公司	Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
AU2003304107B2 (en) *	2002-11-01	2008-05-15	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of preventing infections from bioterrorism agents with immunostimulatory CpG oligonucleotides
EA200600069A1 (ru) *	2003-06-20	2006-08-25	Коли Фармасьютикал Гмбх	Низкомолекулярные антагонисты toll-подобных рецепторов (tlr)
AU2004275876B2 (en) *	2003-09-25	2011-03-31	Coley Pharmaceutical Gmbh	Nucleic acid-lipophilic conjugates
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
US20060019916A1 (en) *	2004-04-02	2006-01-26	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for inducing IL-10 responses
CA2567789A1 (en) *	2004-06-08	2006-08-03	Coley Pharmaceutical Gmbh	Abasic oligonucleotide as carrier platform for antigen and immunostimulatory agonist and antagonist
EP1776105A2 (de) *	2004-07-18	2007-04-25	Coley Pharmaceutical Group, Ltd	Verfahren und zusammensetzungen zur induzierung eigener immunantworten
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
CN101160401A (zh) *	2005-02-24	2008-04-09	科勒制药集团公司	免疫刺激寡核苷酸
US20090117132A1 (en) *	2005-07-07	2009-05-07	Pfizer, Inc.	Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment
US7662949B2 (en) *	2005-11-25	2010-02-16	Coley Pharmaceutical Gmbh	Immunostimulatory oligoribonucleotides
DK1991678T4 (da) *	2006-02-15	2020-10-19	Rechtsanwalt Thomas Beck	Sammensætninger og fremgangsmåder til oligonukleotid-formuleringer

1999
- 1999-05-14 CA CA002328406A patent/CA2328406A1/en not_active Abandoned
- 1999-05-14 EP EP05108933A patent/EP1674574A1/de not_active Withdrawn
- 1999-05-14 DE DE69927495T patent/DE69927495T2/de not_active Expired - Lifetime
- 1999-05-14 WO PCT/IB1999/001285 patent/WO1999058118A2/en not_active Ceased
- 1999-05-14 JP JP2000547969A patent/JP2002514397A/ja active Pending
- 1999-05-14 AU AU45288/99A patent/AU760795B2/en not_active Ceased
- 1999-05-14 EP EP99928176A patent/EP1078053B1/de not_active Expired - Lifetime
- 1999-05-14 NZ NZ508650A patent/NZ508650A/en unknown
- 1999-05-14 AT AT99928176T patent/ATE305507T1/de not_active IP Right Cessation
- 1999-05-14 IL IL13964699A patent/IL139646A0/xx active IP Right Grant
2000
- 2000-11-13 IL IL139646A patent/IL139646A/en not_active IP Right Cessation
2003
- 2003-02-24 US US10/373,381 patent/US20040030118A1/en not_active Abandoned
2004
- 2004-06-25 US US10/876,892 patent/US20040235777A1/en not_active Abandoned
- 2004-06-25 US US10/877,369 patent/US20040234512A1/en not_active Abandoned
- 2004-06-25 US US10/876,965 patent/US20040235778A1/en not_active Abandoned
2006
- 2006-11-10 US US11/595,823 patent/US20070184465A1/en not_active Abandoned
2007
- 2007-12-06 IL IL187987A patent/IL187987A0/en unknown

Also Published As

Publication number	Publication date
DE69927495T2 (de)	2006-07-06
WO1999058118A3 (en)	2000-01-13
AU760795B2 (en)	2003-05-22
NZ508650A (en)	2003-05-30
US20040030118A1 (en)	2004-02-12
US20040235777A1 (en)	2004-11-25
DE69927495D1 (de)	2006-02-09
IL139646A0 (en)	2002-02-10
US20040234512A1 (en)	2004-11-25
AU4528899A (en)	1999-11-29
IL187987A0 (en)	2008-03-20
WO1999058118A2 (en)	1999-11-18
CA2328406A1 (en)	1999-11-18
EP1674574A1 (de)	2006-06-28
US20070184465A1 (en)	2007-08-09
IL139646A (en)	2008-03-20
JP2002514397A (ja)	2002-05-21
EP1078053A2 (de)	2001-02-28
EP1078053B1 (de)	2005-09-28
US20040235778A1 (en)	2004-11-25

Legal Events

Date	Code	Title	Description
2006-03-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE305507T1 (de)	2005-10-15	Verfahren zur regulierung der hematopoiese mit hilfe von cpg oligonukleotide
DE69216062D1 (de)	1997-01-30	Verfahren und vorrichtung zur regelung und zum antrieb von induktionsmotoren.
DE68902375D1 (de)	1992-09-10	Verfahren zur vorsulfidierung von kohlenwasserstoffbehandlungskatalysatoren.
DE69232565D1 (de)	2002-05-23	Verfahren zur behandlung von lungenerkrankungen mit uridin-triphosphaten
DE3776090D1 (de)	1992-02-27	Verfahren zur kontrolle von warenartikeln.
ATE213005T1 (de)	2002-02-15	Kontinuierliches polymerisationverfahren von polyamiden
DE3580412D1 (de)	1990-12-13	Verfahren und vorrichtung zur bewegungssteuerung von magneten.
DE69718027D1 (de)	2003-01-30	Verfahren zur bekämpfung von unkräutern
EP0632894A4 (de)	1997-05-02	Verfahren zur erzeugung homogener reagenzien.
DE69715234D1 (de)	2002-10-10	Verfahren zur reinigung von 1,1-difluorethan
DE59300338D1 (de)	1995-08-17	Mittel und Verfahren zur Ausrüstung von Textilien.
DE69710078D1 (de)	2002-03-14	Verfahren zur reinigung von 1,1,1,3,3-pentafluorpropan
EP0656791A4 (de)	1997-08-20	Therapeutische zusammensetzungen und verfahren unter verwendung von pqq.
EP0850067A4 (de)	1999-12-15	Verfahren zur krebsbehandlung unter verwendung von 6-(3-(1-adamantyl)-4-hydroxyphenyl)2 naphtalincarbonsäure
ATE118498T1 (de)	1995-03-15	Verfahren zur reinigung von n- phosphonmethylglyzin.
DE69325452D1 (de)	1999-07-29	Verfahren zur herstellung von (s)-3-amino-1-substituiert-pirrolidine
ATA39595A (de)	1997-03-15	Verfahren zur gewinnung bzw. rückgewinnung von säuren
DE69001050D1 (de)	1993-04-15	Verfahren um oktanbedarfserhoehungsreglerzusaetze zur erzeugen.
DE3685662D1 (de)	1992-07-23	N-substituierte phenylteraconimidverbindung, herbizidzusammensetzung und verfahren zur kontrolle von unerwuenschtem unkraut.
DE3770967D1 (de)	1991-08-01	Verfahren zur beherrschung von unkraut.
DE69323615D1 (de)	1999-04-01	Verfahren zur kontrolle von baumwuchs
DE69006509D1 (de)	1994-03-17	Verfahren zur behandlung von häuten.
DE59001866D1 (de)	1993-07-29	Verfahren zur biologischen abwasserbehandlung mit hilfe von mikroorganismen.
DE69314644D1 (de)	1997-11-20	Verfahren zur isomerisierung von 1,1,2-trichlortrifluorethan
DE69112391D1 (de)	1995-09-28	Verfahren zur reinigung von fluorwasserstoff.